Abstract
Neurodegenerative diseases (NDs) are a group of chronic, progressive disorders characterized by the gradual loss of neurons that affect specific regions of the brain, which leads to deficits in specific functions (e.g., memory, movement, cognition). The mechanism that drives chronic progression of NDs remains elusive. Among the proposed underlying pathophysiological mechanisms, aggregation and accumulation of misfolded proteins and neuroinflammation have been credited to contribute to extensive neural loss. Therapeutic agents that confer neuroprotection by downregulating these shared characteristics could therefore have beneficial effects on a wide range of NDs. In this regard, a commonly used antibiotic, doxycycline (Doxy), has been shown to reduce the progression and severity of disease in different experimental models of neurodegeneration by counteracting these common features. This review will focus on the effects reported for Doxy regarding its neuroprotective properties, the “off-target” effects, thereby supporting its evaluation as a new therapeutic approach for diseases associated with a neurodegeneration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahler E, Sullivan WJ, Cass A, Braas D, York AG, Bensinger SJ, Graeber TG, Christofk HR (2013) Doxycycline alters metabolism and proliferation of human cell lines. PLoS One 8:e64561. https://doi.org/10.1371/journal.pone.0064561
Balducci C, Santamaria G, la Vitola P, Brandi E, Grandi F, Viscomi AR, Beeg M, Gobbi M, Salmona M, Ottonello S, Forloni G (2018) Doxycycline counteracts neuroinflammation restoring memory in Alzheimer’s disease mouse models. Neurobiol Aging 70:128–139. https://doi.org/10.1016/j.neurobiolaging.2018.06.002
Bortolanza M, Nascimento GC, Socias SB, Ploper D, Chehin RN, Raisman-Vozari R, Del-Bel E (2018) Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease. J Neural Transm 125:1403–1415. https://doi.org/10.1007/s00702-018-1913-1
Brezovakova V, Valachova B, Hanes J, Novak M, Jadhav S (2018) Dendritic cells as an alternate approach for treatment of neurodegenerative disorders. Cell Mol Neurobiol 38:1207–1214. https://doi.org/10.1007/s10571-018-0598-1
Chen WW, Zhang X, Huang WJ (2016) Role of neuroinflammation in neurodegenerative diseases (review). Mol Med Rep 13:3391–3396. https://doi.org/10.3892/mmr.2016.4948
Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ, Choi DH, Joh TH, Kim YS, Hwang O (2009) Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 16:361–371. https://doi.org/10.1007/s12640-009-9078-1
Chui DH, Tabira T, Izumi S, Koya G, Ogata J (1994) Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. Am J Pathol 145:771–775
Collins SJ, Lawson VA, Masters CL (2004) Transmissible spongiform encephalopathies. Lancet 363:51–61. https://doi.org/10.1016/S0140-6736(03)15171-9
Costa R, Speretta E, Crowther DC, Cardoso I (2011) Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. J Biol Chem 286:41647–41655. https://doi.org/10.1074/jbc.M111.274548
De Luigi A et al (2008) The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 3:e1888. https://doi.org/10.1371/journal.pone.0001888
Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G (2015) Anti-inflammatory properties of low and high doxycycline doses: an in vitro study Mediators of inflammation. Mediat Inflamm 2015:329418. https://doi.org/10.1155/2015/329418
Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, de Luigi A, Salmona M (2010) Tetracycline and its analogues protect Caenorhabditis elegans from beta amyloid-induced toxicity by targeting oligomers. Neurobiol Dis 40:424–431. https://doi.org/10.1016/j.nbd.2010.07.002
Dohm CP, Kermer P, Bahr M (2008) Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication. Neurodegener Dis 5:321–338. https://doi.org/10.1159/000119459
Domercq M, Matute C (2004) Neuroprotection by tetracyclines. Trends Pharmacol Sci 25:609–612. https://doi.org/10.1016/j.tips.2004.10.001
Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487:404–407
Forloni G, Salmona M, Marcon G, Tagliavini F (2009) Tetracyclines and prion infectivity. Infect Disord Drug Targets 9:23–30
Forloni G, Artuso V, Roiter I, Morbin M, Tagliavini F (2013) Therapy in prion diseases. Curr Top Med Chem 13:2465–2476
Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, Erbetta A, Villani F, Redaelli V, Tagliavini F, Artuso V, Roiter I (2015) Preventive study in subjects at risk of fatal familial insomnia: innovative approach to rare diseases. Prion 9:75–79. https://doi.org/10.1080/19336896.2015.1027857
Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55:259–272
Gandhi S, Wood NW (2005) Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet 14:2749–2755. https://doi.org/10.1093/hmg/ddi308
Golub LM, Elburki MS, Walker C, Ryan M, Sorsa T, Tenenbaum H, Goldberg M, Wolff M, Gu Y (2016) Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. Int Dent J 66:127–135. https://doi.org/10.1111/idj.12221
Gonzalez-Lizarraga F et al (2017) Repurposing doxycycline for synucleinopathies: remodelling of alpha-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Sci Rep 7:41755. https://doi.org/10.1038/srep41755
Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V (2015) Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J 471:323–333. https://doi.org/10.1042/BJ20150617
Haik S et al (2014) Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:150–158. https://doi.org/10.1016/S1474-4422(13)70307-7
Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372. https://doi.org/10.1038/nrn3880
Inglese M, Petracca M (2013) Imaging multiple sclerosis and other neurodegenerative diseases. Prion 7:47–54. https://doi.org/10.4161/pri.22650
Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386:896–912. https://doi.org/10.1016/S0140-6736(14)61393-3
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486–489. https://doi.org/10.1126/science.1079469
Keijmel SP, Delsing CE, Bleijenberg G, van der Meer JWM, Donders RT, Leclercq M, Kampschreur LM, van den Berg M, Sprong T, Nabuurs-Franssen MH, Knoop H, Bleeker-Rovers CP (2017) Effectiveness of long-term doxycycline treatment and cognitive-behavioral therapy on fatigue severity in patients with Q fever fatigue syndrome (Qure study): a randomized controlled trial. Clin Infect Dis 64:998–1005. https://doi.org/10.1093/cid/cix013
Lassmann H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585:3715–3723. https://doi.org/10.1016/j.febslet.2011.08.004
Lazzarini M, Martin S, Mitkovski M, Vozari RR, Stuhmer W, Bel ED (2013) Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model. Glia 61:1084–1100. https://doi.org/10.1002/glia.22496
Lucchetti J, Fracasso C, Balducci C, Passoni A, Forloni G, Salmona M, Gobbi M (2019) Plasma and brain concentrations of doxycycline after single and repeated doses in wild-type and APP23 mice. J Pharmacol Exp Ther 368:32–40. https://doi.org/10.1124/jpet.118.252064
McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 27:741–749. https://doi.org/10.1016/S0278-5846(03)00124-6
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ (2008) Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 65:199–204. https://doi.org/10.1001/archneurol.2007.41
Nelson ML, Levy SB (2011) The history of the tetracyclines. Ann N Y Acad Sci 1241:17–32. https://doi.org/10.1111/j.1749-6632.2011.06354.x
Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124:2203–2214
Noble W, Garwood CJ, Hanger DP (2009) Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3:78–83
Prusiner SB (2001) Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 344:1516–1526. https://doi.org/10.1056/NEJM200105173442006
Reglodi D, Renaud J, Tamas A, Tizabi Y, Socias SB, Del-Bel E, Raisman-Vozari R (2017) Novel tactics for neuroprotection in Parkinson’s disease: role of antibiotics, polyphenols and neuropeptides. Prog Neurobiol 155:120–148. https://doi.org/10.1016/j.pneurobio.2015.10.004
Rotermund C, Machetanz G, Fitzgerald JC (2018) The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol 9:400. https://doi.org/10.3389/fendo.2018.00400
Santa-Cecilia FV et al (2016) Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-kB signaling pathways. Neurotox Res 29:447–459. https://doi.org/10.1007/s12640-015-9592-2
Schmitz M, Cramm M, Llorens F, Candelise N, Müller-Cramm D, Varges D, Schulz-Schaeffer WJ, Zafar S, Zerr I (2016) Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie. Sci Rep 6:28711. https://doi.org/10.1038/srep28711
Skaper SD (2007) The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 1122:23–34. https://doi.org/10.1196/annals.1403.002
Socias SB, González-Lizárraga F, Avila CL, Vera C, Acuña L, Sepulveda-Diaz JE, del-Bel E, Raisman-Vozari R, Chehin RN (2018) Exploiting the therapeutic potential of ready-to-use drugs: repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Prog Neurobiol 162:17–36. https://doi.org/10.1016/j.pneurobio.2017.12.002
Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65:184–189. https://doi.org/10.1001/archneurol.2007.56
Starckx S, Van den Steen PE, Verbeek R, van Noort JM, Opdenakker G (2003) A novel rationale for inhibition of gelatinase B in multiple sclerosis: MMP-9 destroys alpha B-crystallin and generates a promiscuous T cell epitope. J Neuroimmunol 141:47–57
Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Schulz-Schaeffer WJ, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I (2017) Doxycycline in early CJD: a double-blinded randomised phase II and observational study. J Neurol Neurosurg Psychiatry 88:119–125. https://doi.org/10.1136/jnnp-2016-313541
Zhang GB, Feng YH, Wang PQ, Song JH, Wang P, Wang SA (2015) A study on the protective role of doxycycline upon dopaminergic neuron of LPS-PD rat model rat. Eur Rev Med Pharmacol Sci 19:3468–3474
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Santa-Cecília, F.V., Leite, C.A., Del-Bel, E. et al. The Neuroprotective Effect of Doxycycline on Neurodegenerative Diseases. Neurotox Res 35, 981–986 (2019). https://doi.org/10.1007/s12640-019-00015-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-019-00015-z